Orchiectomy
 

Orchiectomy

Back to Top

Surgery Overview

Orchiectomy is the removal of the testicles, a man's main source of testosterone, which prostate cancer usually needs to continue growing.

Back to Top

What To Expect After Surgery

Orchiectomy can be done as an outpatient procedure or with a short hospital stay. Regular activities are usually resumed within 1 to 2 weeks, and a full recovery can be expected within 2 to 4 weeks.

Back to Top

Why It Is Done

Orchiectomy may help relieve symptoms, prevent complications, and prolong survival for advanced prostate cancer. Radiation treatment is sometimes needed as well.

Back to Top

How Well It Works

Orchiectomy often causes the tumor to shrink and relieves bone pain.

This surgery does not cure prostate cancer, although it may prolong survival.

Back to Top

Risks

Orchiectomy causes sudden hormone changes in the body. Side effects from hormone changes include:

  • Sterility.
  • Loss of sexual interest.
  • Erection problems.
  • Hot flashes.
  • Larger breasts (gynecomastia).
  • Weight gain.
  • Loss of muscle mass.
  • Thin or brittle bones (osteoporosis)
Back to Top

What To Think About

Removing the testicles has the same effect as hormone treatment. Some men may prefer surgery over hormone therapy, which involves taking pills daily or having injections every 1 to 4 months. And orchiectomy costs less overall. But a benefit of hormone therapy is that you can stop taking the hormone drugs, while an orchiectomy is permanent.

Some men choose to have reconstructive surgery after an orchiectomy, in which the surgeon replaces the testicles with artificial testicles.

Complete the surgery information form (PDF)Click here to view a form.(What is a PDF document?) to help you prepare for this surgery.

Back to Top

Credits

AuthorKathe Gallagher, MSW
EditorKathleen M. Ariss, MS
Associate EditorTerrina Vail
Primary Medical ReviewerMartin Gabica, MD
- Family Medicine
Specialist Medical ReviewerChristopher G. Wood, MD, FACS
- Urology/Oncology
Last UpdatedJuly 24, 2006
Latest Cancer News
Zevalin® Confirmed Effective for Patients with Follicular Lymphoma Who Have Failed an Autologous Transplant

September 5, 2008 — Researchers from France have reported that five of eight patients with follicular lymphoma who had failed an autologous stem cell transplant achieved a complete remission with standard doses of Zevalin® (Yttrium-90 ((90)Y) ibritumomab tiuxetan). The details of this study appeared in an early online publication in Leukemia-Lymphoma of July 15, 2008.

Forty Percent of Postmenopausal Breast Cancers Preventable by Lifestyle Changes

September 5, 2008 — Researchers from the University of Wisconsin-Madison, the H. Lee Moffitt Cancer Center, Dartmouth Medical School, and the Fred Hutchinson Cancer Center have reported that 40.7% of postmenopausal breast cancer can be prevented by changes in lifestyle. The details of this study appeared in the August 15, 2008 issue of the American Journal of Epidemiology.

US FDA lists drugs under safety probes

September 5, 2008 — WASHINGTON (Reuters) - U.S. health officials said on Friday they are probing safety concerns with Eli Lilly and Co's antidepressant Cymbalta, Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri and more than a dozen other medicines.

Select news items provided by Reuters Health